pharma · Polycythemia Vera · Ulcerative Colitis Chronic Moderate · PTGX
Protagonist Therapeutics
Protagonist Therapeutics, Inc
Protagonist Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 7707 Gateway Blvd, Suite 140, Newark, California 94560, US
- Founded
- 2006
- Employees
- 153
- Programs
- 13
- Drugs
- 5
- Patents
- 33
Protagonist Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Protagonist Therapeutics.
Protagonist Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PN-943
Protagonist Therapeutics, Inc
Ulcerative Colitis Chronic Moderate
1 trial -
PTG-100
Protagonist Therapeutics, Inc
Ulcerative Colitis
1 trial -
PTG-300
Protagonist Therapeutics, Inc
Hereditary Hemochromatosis
1 trial -
PTG-300
Protagonist Therapeutics, Inc
Polycythemia Vera
2 trials -
PTG-300
Protagonist Therapeutics, Inc
β-thalassemia
2 trials
Frequently asked questions
How many clinical projects does Protagonist Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.